Furthermore, when untreated tumor cells were incubated in OXA-containing CM, the addition of exogenous VEGF (2.5 ng/mL) to the CM obtained after co-treatment with low-concentration EGCG and OXA caused a decrease in tumor cell sensitivity to 2nd OXA treatment (Fig. 3c). This evidence concerns the gene VEGFA and neoplasm.